Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 409

1.

Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.

Masuishi T, Taniguchi H, Kotani D, Bando H, Komatsu Y, Shinozaki E, Nakajima TE, Satoh T, Nishina T, Esaki T, Wakabayashi M, Nomura S, Takahashi K, Ono H, Hirano N, Fujishiro N, Fuse N, Sato A, Ohtsu A, Yoshino T.

ESMO Open. 2019 Nov 13;4(6):e000590. doi: 10.1136/esmoopen-2019-000590. eCollection 2019.

2.

Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma.

Hatogai K, Fujii S, Kitano S, Kojima T, Daiko H, Yoshino T, Ohtsu A, Takiguchi Y, Doi T, Ochiai A.

Br J Cancer. 2019 Nov 25. doi: 10.1038/s41416-019-0622-3. [Epub ahead of print]

PMID:
31761900
3.

RNA sequencing for ligature induced periodontitis in mice revealed important role of S100A8 and S100A9 for periodontal destruction.

Maekawa S, Onizuka S, Katagiri S, Hatasa M, Ohsugi Y, Sasaki N, Watanabe K, Ohtsu A, Komazaki R, Ogura K, Miyoshi-Akiyama T, Iwata T, Nitta H, Izumi Y.

Sci Rep. 2019 Oct 11;9(1):14663. doi: 10.1038/s41598-019-50959-7.

4.

Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing.

Fujii S, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shinozaki E, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K.

Biomed Rep. 2019 Oct;11(4):171-180. doi: 10.3892/br.2019.1235. Epub 2019 Aug 21.

5.

JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.

Yoshino T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Munemoto Y, Takagane A, Ishikawa H, Ishida H, Ogata Y, Oba K, Goto K, Sakamoto J, Maehara Y, Ohtsu A.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1269-1277. doi: 10.1007/s00280-019-03957-5. Epub 2019 Sep 23.

6.

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.

Yoshino T, Yamanaka T, Oki E, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Takeuchi S, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Mizushima T, Saji S, Maehara Y, Ohtsu A, Mori M.

JAMA Oncol. 2019 Sep 12. doi: 10.1001/jamaoncol.2019.2572. [Epub ahead of print]

PMID:
31513248
7.

Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma.

Yamazaki K, Doi T, Ikeda M, Okusaka T, Schueler A, Watanabe M, Ohtsu A.

Cancer Chemother Pharmacol. 2019 Nov;84(5):1027-1037. doi: 10.1007/s00280-019-03924-0. Epub 2019 Sep 3.

PMID:
31482223
8.

Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts.

Kuwata T, Yanagihara K, Iino Y, Komatsu T, Ochiai A, Sekine S, Taniguchi H, Katai H, Kinoshita T, Ohtsu A.

Cells. 2019 Jun 14;8(6). pii: E585. doi: 10.3390/cells8060585.

9.

Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

Kirschbrown WP, Wang B, Nijem I, Ohtsu A, Hoff PM, Shah MA, Shen L, Kang YK, Alsina M, Girish S, Garg A.

Cancer Chemother Pharmacol. 2019 Sep;84(3):539-550. doi: 10.1007/s00280-019-03871-w. Epub 2019 Jun 10.

10.

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.

Harada K, Okamoto W, Mimaki S, Kawamoto Y, Bando H, Yamashita R, Yuki S, Yoshino T, Komatsu Y, Ohtsu A, Sakamoto N, Tsuchihara K.

BMC Cancer. 2019 Mar 21;19(1):255. doi: 10.1186/s12885-019-5479-6.

11.

KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer.

Bang YJ, Van Cutsem E, Fuchs CS, Ohtsu A, Tabernero J, Ilson DH, Hyung WJ, Strong VE, Goetze TO, Yoshikawa T, Tang LH, Hwang PMT, Webb N, Adelberg D, Shitara K.

Future Oncol. 2019 Mar;15(9):943-952. doi: 10.2217/fon-2018-0581. Epub 2019 Feb 19.

12.

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

Shah MA, Kang YK, Thuss-Patience PC, Ohtsu A, Ajani JA, Van Cutsem E, Hoersch S, Harle-Yge ML, de Haas SL.

Gastric Cancer. 2019 Jul;22(4):803-816. doi: 10.1007/s10120-018-00923-7. Epub 2019 Jan 31.

PMID:
30706247
13.

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.

Mishima S, Kawazoe A, Nakamura Y, Sasaki A, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Tsuji A, Shitara K.

J Immunother Cancer. 2019 Jan 31;7(1):24. doi: 10.1186/s40425-019-0514-3.

14.

Influence of Porphyromonas gingivalis in gut microbiota of streptozotocin-induced diabetic mice.

Ohtsu A, Takeuchi Y, Katagiri S, Suda W, Maekawa S, Shiba T, Komazaki R, Udagawa S, Sasaki N, Hattori M, Izumi Y.

Oral Dis. 2019 Apr;25(3):868-880. doi: 10.1111/odi.13044. Epub 2019 Feb 10.

PMID:
30667148
15.

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.

Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Akimoto T, Shitara K.

Gastric Cancer. 2019 Jul;22(4):793-802. doi: 10.1007/s10120-018-00922-8. Epub 2019 Jan 9.

PMID:
30627987
16.

Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials.

Chau I, Fuchs CS, Ohtsu A, Barzi A, Liepa AM, Cui ZL, Hsu Y, Al-Batran SE.

Eur J Cancer. 2019 Jan;107:115-123. doi: 10.1016/j.ejca.2018.11.013. Epub 2018 Dec 14.

17.

Poster abstracts of the 18th Pan Arab Cancer Congress. TUNISIA. April 19-21, 2018.

Aarab J, Abbess I, Abdalla F, Abdelaziz Z, Abdelfattah S, Abdelli I, Abdelmajid K, Abdelsselem Z, Abdelwahed N, Abdessayed N, Abid B, Abid K, Abidi R, Abudabbous A, Abujanah S, Aburwais A, Acacha E, Acharfi N, Affes N, Aftis R, Ahalli I, Aid M, Aissaoui D, Alaoui A, Alaoui M, Albatran S, Mamdouh A, Alkikkli R, Allam A, Aloulou S, Alqawi O, Alragig MA, Alsharksi A, Amaadour KOL, Amaadour L, Ameziane N, Ammari A, Ammour H, Amrane R, Annad N, Aouati E, Aouichat S, Aouragh S, Arifi S, Astra M, Atassi M, Ati N, Atoui K, Atreche L, Ayachi S, Ayadi I, Ayadi MA, Ayadi M, Ayari J, Ayed H, Ayed K, Ayedi H, Ayedi I, Azegrar M, Azzouz H, Babdalla F, Bachiri R, Bachiri Z, Baghdad M, Bahloul R, Bahouli A, Bahri M, Baississ I, Bakkali H, Balti M, Baraket O, Bargaoui H, Batti R, Bedioui A, Begag R, Behourah Z, Belaid I, Belaïd A, Ben Abdallah A, Ben Abdallah I, Ben Ahmed S, Ben Ahmed T, Ben Azaiz M, Ben Chehida MA, Ben Fatma L, Ben Ghachem D, Ben Ghachem T, Ben Hassouna J, Ben Hmida S, Ben Nasr S, Ben Nejima D, Ben Rahal K, Ben Rejeb M, Ben Rhouma S, Ben Safta I, Ben Salem A, Ben Zargouna Y, Benabdallah I, Benabdella H, Benabdessalem MZ, Benahmed K, Benahmed S, Benameur H, Benasr S, Benbrahim F, Benbrahim W, Benbrahim Z, Benchehida M, Bencheikh Y, Bendhiab T, Benfatma L, Bengueddach A, Benhami M, Benhassouna J, Benhbib W, Benjaafar N, Benkali R, Benkridis W, Benlaloui A, Benmaitig M, Benmansour A, Benmouhoub M, Benna F, Benna H, Benna M, Benna M, Bennabdellah H, Benrahal K, Bensafta I, Bensalah H, Bensalem A, Bensaud M, Benslama R, Benyoub M, Benzid K, Bergaoui H, Beroual M, Berrad S, Berrazaga Y, Bezzaz Z, Bhiri H, Bibi M, Binous MY, Blel A, Boder JM, Bouaouina N, Bouaziz H, Bouchoucha S, Boudawara T, Boudawara Z, Bouderbala A, Bouhali R, Bouhani M, Boujarnija R, Boujelben S, Boujelbene N, Boukerzaza I, Boukhari H, Boulfoul W, Boulma R, Boumansour N, Bouned A, Bounedjar A, Bouraoui I, Bouraoui S, Bourigua R, Bourmech M, Bousaffa H, Bousahba A, Bousrih C, Boussarsar A, Boussen H, Boutayeb S, Bouzaidi K, Bouzaiene F, Bouzaiene H, Bouzerzour Z, Bouzid K, Bouzid N, Bouzidi D, Bouzidi W, Bouzouita A, Brahimi S, Brahmia A, Buhmeida A, Chaaben K, Chaabouni H, Chaabouni M, Chaabène K, Chaari H, Chaari I, Chaari M, Chabchoub I, Chabeene K, Chaker K, Chakroun M, Charfi M, Charfi S, Chargui R, Charles M, Chebil M, Cheikchouk K, Chelly B, Chelly I, Cheraiet N, Cherif A, Cherif M, Cherifi A, Chikhrouhou T, Chikouche A, Chirouf A, Chraiet N, Collan Y, Cui Z, Dabbebi H, Daldoul A, Damouche I, Daoud H, Daoud N, Daoued J, Darif K, Darwish DO, Derbouz Z, Derouiche A, Dhibe TT, Dhibet T, Djallaoui A, Djami N, Djebbes K, Djedi H, Djeghim S, Djellali L, Djellaoui A, Djilat K, Djouabi R, Doumbia H, Drah M, Dridi M, Hsairi M, Elabbassi S, Elallia F, Elati Z, Elattassi M, Elbenna H, Elfagieh MA, Elfaitori O, Elfannas H, Elghali A, Elghali MA, Elgonti S, Elhadj OE, Elhazzaz R, Elkacemi H, Elkinany K, Elkissi Y, Elloumi F, Elmaalel O, Elmajjaou IS, Elmajjaoui S, Elmhabrech H, Elmrabet F, Elsaghayer WA, Elzagheid A, Emaetig F, Erraichi H, Essid M, Ewshah N, Ezzairi F, Faleh R, Fallah S, Farag AL, Farhat L, Fehri R, Feki J, Fendri S, Fendri S, Fessi Z, Filali T, Fissah A, Fourati M, Fourati N, Frikha M, Fuchs CS, Gabssi A, Gachi F, Gadria S, Gammoudi A, Ganzoui I, Gargoura A, Ghaddabb I, Gharbi I, Gharbi M, Ghazouani E, Gheriani N, Ghorbel A, Ghorbel L, Ghozi A, Ghrissi R, Gouader A, Goucha A, Guebsi A, Guellil I, Guermazi F, Guesmi S, Guetari W, Habak N, Haddad A, Haddad S, Haddaoui A, Hadef I, Hader AF, Hadiji A, Hadjarab F, Hadoussa M, Hadoussa N, Hafsa C, Hafsia M, Hajji A, Hajmansour M, Hamdi S, Hamici Z, Hamida S, Hamila F, Hamissa S, Hammouda B, Haouet S, Harhira I, Haroun A, Hassouni K, Hdiji A, Hechiche M, Hejjane L, Hellal C, Henni M, Herbegue K, Hichami L, Hikem M, Hmad A, Hmida L, Hmissa S, Hochlaf M, Houas A, Houhani M, Huwidi A, Ian C, Ibrahim BN, Ibrahim NY, Idir H, Issaoui D, Itaimi A, Izem AE, Jaidane O, Jamel D, Jamous H, Jarrar M, Jarrar MS, Jarray S, Jebsi M, Jmal H, Juwid A, Kaabia O, Kablouti A, Kacem I, Kacem K, Kaid MY, Kallel M, Kallel R, Kammoun H, Kari S, Karrit S, Kchir H, Kchir N, Kebdani T, Kechad N, Kehili H, Kerboua E, Keskes H, Kessi NN, Khababa N, Khaldi H, Khanfir A, Khater B, Khelif A, Khemiri S, Khennouf K, Khouni H, Khrouf S, Kmira Z, Kochbati L, Korbi A, Kouadri N, Kouhen F, Krarti M, Handoussa M, Hsu Y, Laakom O, Laato M, Labidi S, Lahlali F, Lahmidi A, Lalaoui A, Lamia N, Lamri A, Letaief F, Letaief MR, Aldehmani M, Rafael A, Liepa AM, Limaiem F, Limam K, Loughlimi H, Ltaief F, Maamouri N, Mabrouk M, Madouri R, Mahjoub N, Mahjoubi Z, Mahrsi M, Makrem H, Mallek W, Manitta M, Mansoura L, Mansouri H, Maoua M, Maoui W, Marouene C, Marzouk K, Masmoudi S, May F, Meddeb I, Meddeb K, Meddour S, Medhioub F, Mejri N, Melizi MR, Mellas N, Melliti R, Melzi A, Merair N, Merrouki FZ, Mersali C, Messalbi O, Messaoudi L, Messioud S, Messoudi K, Mestiri S, Mezlini A, Mezlini A, Mghirbi F, Mhabrech H, Mhiri A, Midoun N, Milud R, Missaoui B, Mnasser A, Mnejja W, Mokni M, Mokrani A, Mokrani M, Moujahed R, Moukasse Y, Mouzount A, Mrad K, Mraidha MH, Mrizak N, Mzali R, Mzid Y, M'ghirbi F, Nakhli A, Nasr C, Nasri S, Noubigh G, Nouha D, Nouia L, Nouira Y, Noureddine A, Nouri O, Ohtsu A, Ouahbi H, Oualla K, Ouanes Y, Ouaz H, Ouikene A, Ouldbessi N, Parker I, Pyrhonen S, Rachdi H, Rahal K, Rahal K, Rahoui M, Raies H, Rameh S, Reguieg K, Rejab H, Rejiba R, Rhim MS, Riahi S, Rouimel N, Saad Saoud N, Saadi K, Saadi M, Sadou A, Saguem I, Sahnoun T, Sahnoune H, Sakhri S, Sallemi A, Sassi A, Sbika W, Sedkaoui C, Sefiane S, Sellami A, Seppo P, Sfaoua H, Sghaier S, Shagan A, Siala W, Slim I, Slimene M, Soltani S, Souilah S, Souissi M, Sriha Badreddine B, Swaisi Y, Taibi A, Taktak T, Talbi G, Talha SW, Talima SM, Tbessi S, Tebani N, Tebra S, Tebramrad S, Telaijia D, Tenni A, Tolba A, Topov Y, Touil K, Toumi N, Toumi W, Tounsi N, Trigui A, Trigui R, Triki W, Walha M, Werda I, Yacoub H, Yahyaoui Y, Yaich A, Yaici R, Yamouni M, Yeddes I, Yekrou D, Yousfi M, Yousfi N, Youssfi MA, Zaabar L, Zaied S, Zaim I, Zakhama W, Zayed S, Zehani A, Zemni I, Zenzri Y, Zeraoula S, Zouiten O, Zoukar O, Zrafi W, Zribi A, Zubia N.

Tunis Med. 2018 Apr;96(4):177-182. No abstract available.

18.

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma.

Mishima S, Kawazoe A, Matsumoto H, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Nonte EM, Chintharlapalli S, Nasir A, Kuwata T, Shitara K.

ESMO Open. 2018 Nov 1;3(7):e000443. doi: 10.1136/esmoopen-2018-000443. eCollection 2018.

19.

Endotoxemia by Porphyromonas gingivalis Injection Aggravates Non-alcoholic Fatty Liver Disease, Disrupts Glucose/Lipid Metabolism, and Alters Gut Microbiota in Mice.

Sasaki N, Katagiri S, Komazaki R, Watanabe K, Maekawa S, Shiba T, Udagawa S, Takeuchi Y, Ohtsu A, Kohda T, Tohara H, Miyasaka N, Hirota T, Tamari M, Izumi Y.

Front Microbiol. 2018 Oct 24;9:2470. doi: 10.3389/fmicb.2018.02470. eCollection 2018.

20.

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.

Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, Song C, Wu H, Eng-Wong J, Kim K, Kang YK.

Lancet Oncol. 2018 Oct;19(10):1372-1384. doi: 10.1016/S1470-2045(18)30481-9. Epub 2018 Sep 11.

PMID:
30217672
21.

Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.

Yoshino T, Yamazaki K, Shinozaki E, Komatsu Y, Nishina T, Baba H, Tsuji A, Tsuji Y, Yamaguchi K, Sugimoto N, Denda T, Muro K, Takayama T, Esaki T, Hamamoto Y, Moriwaki T, Shimada Y, Goto M, Nakayama N, Fujii H, Tanase T, Ohtsu A.

Clin Colorectal Cancer. 2018 Dec;17(4):e719-e732. doi: 10.1016/j.clcc.2018.07.009. Epub 2018 Jul 26.

22.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators.

Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.

PMID:
29880231
23.

Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.

Kawazoe A, Shitara K, Kuboki Y, Bando H, Kojima T, Yoshino T, Ohtsu A, Ochiai A, Togashi Y, Nishikawa H, Doi T, Kuwata T.

Gastric Cancer. 2019 Jan;22(1):69-76. doi: 10.1007/s10120-018-0843-9. Epub 2018 Jun 1.

PMID:
29859006
24.

Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer.

Kotaka M, Yamanaka T, Yoshino T, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Gamoh M, Shiozawa M, Saji S, Maehara Y, Mizushima T, Ohtsu A, Mori M.

ESMO Open. 2018 Apr 24;3(3):e000354. doi: 10.1136/esmoopen-2018-000354. eCollection 2018.

25.

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.

Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH.

JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May 10.

26.

Author Correction: Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism.

Komazaki R, Katagiri S, Takahashi H, Maekawa S, Shiba T, Takeuchi Y, Kitajima Y, Ohtsu A, Udagawa S, Sasaki N, Watanabe K, Sato N, Miyasaka N, Eguchi Y, Anzai K, Izumi Y.

Sci Rep. 2018 Mar 12;8(1):4620. doi: 10.1038/s41598-018-23000-6.

27.

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.

Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, Tebbutt NC, Markman B, Price T, Esaki T, Koski S, Hitron M, Li W, Li Y, Magoski NM, Li CJ, Simes J, Tu D, O'Callaghan CJ.

Lancet Gastroenterol Hepatol. 2018 Apr;3(4):263-270. doi: 10.1016/S2468-1253(18)30009-8. Epub 2018 Feb 1.

PMID:
29397354
28.

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.

Matsumoto H, Kawazoe A, Shimada K, Fukuoka S, Kuboki Y, Bando H, Kojima T, Ohtsu A, Yoshino T, Doi T, Shitara K.

BMC Cancer. 2018 Jan 31;18(1):120. doi: 10.1186/s12885-018-4057-7.

29.

Effect of Porphyromonas gingivalis infection in the placenta and umbilical cord in pregnant mice with low birth weight.

Udagawa S, Katagiri S, Maekawa S, Takeuchi Y, Komazaki R, Ohtsu A, Sasaki N, Shiba T, Watanabe K, Ishihara K, Sato N, Miyasaka N, Izumi Y.

Acta Odontol Scand. 2018 Aug;76(6):433-441. doi: 10.1080/00016357.2018.1426876. Epub 2018 Jan 15.

PMID:
29334319
30.

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.

Van Cutsem E, Mayer RJ, Laurent S, Winkler R, Grávalos C, Benavides M, Longo-Munoz F, Portales F, Ciardiello F, Siena S, Yamaguchi K, Muro K, Denda T, Tsuji Y, Makris L, Loehrer P, Lenz HJ, Ohtsu A; RECOURSE Study Group.

Eur J Cancer. 2018 Feb;90:63-72. doi: 10.1016/j.ejca.2017.10.009. Epub 2017 Dec 21.

31.

Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial.

Van Cutsem E, Falcone A, Garcia-Carbonero R, Komatsu Y, Pastorino A, Peeters M, Shimada Y, Yamazaki K, Yoshino T, Zaniboni A, Amellal N, Kanehisa A, Winkler R, Makris L, Mayer RJ, Ohtsu A, Tabernero J.

ESMO Open. 2017 Nov 23;2(5):e000261. doi: 10.1136/esmoopen-2017-000261. eCollection 2017.

32.

QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer.

Tabernero J, Van Cutsem E, Ohtsu A, Amellal N, Cadour S, Fougeray R, Haffemayer B, Mayer RJ.

ESMO Open. 2017 Nov 23;2(5):e000284. doi: 10.1136/esmoopen-2017-000284. eCollection 2017.

33.

Integrated safety summary for trifluridine/tipiracil (TAS-102).

Falcone A, Ohtsu A, Van Cutsem E, Mayer RJ, Buscaglia M, Bendell JC, Kopetz S, Bebeau P, Yoshino T.

Anticancer Drugs. 2018 Jan;29(1):89-96. doi: 10.1097/CAD.0000000000000554.

PMID:
29176395
34.

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Mastura MY, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY.

Ann Oncol. 2018 Jan 1;29(1):44-70. doi: 10.1093/annonc/mdx738.

PMID:
29155929
35.

Advanced glycation end products and lipopolysaccharides stimulate interleukin-6 secretion via the RAGE/TLR4-NF-κB-ROS pathways and resveratrol attenuates these inflammatory responses in mouse macrophages.

Ohtsu A, Shibutani Y, Seno K, Iwata H, Kuwayama T, Shirasuna K.

Exp Ther Med. 2017 Nov;14(5):4363-4370. doi: 10.3892/etm.2017.5045. Epub 2017 Aug 28.

36.

Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism.

Komazaki R, Katagiri S, Takahashi H, Maekawa S, Shiba T, Takeuchi Y, Kitajima Y, Ohtsu A, Udagawa S, Sasaki N, Watanabe K, Sato N, Miyasaka N, Eguchi Y, Anzai K, Izumi Y.

Sci Rep. 2017 Oct 24;7(1):13950. doi: 10.1038/s41598-017-14260-9. Erratum in: Sci Rep. 2018 Mar 12;8(1):4620.

37.

Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.

Sawaki A, Yamada Y, Yamaguchi K, Nishina T, Doi T, Satoh T, Chin K, Boku N, Omuro Y, Komatsu Y, Hamamoto Y, Koizumi W, Saji S, Shah MA, Van Cutsem E, Kang YK, Iwasaki J, Kuriki H, Ohtsuka W, Ohtsu A.

Gastric Cancer. 2018 May;21(3):429-438. doi: 10.1007/s10120-017-0773-y. Epub 2017 Oct 20.

38.

A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer.

Tanase T, Hamada C, Yoshino T, Ohtsu A.

Anticancer Res. 2017 Oct;37(10):5851-5855.

PMID:
28982911
39.

Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation.

Enokida T, Fujii S, Takahashi M, Higuchi Y, Nomura S, Wakasugi T, Yamazaki T, Hayashi R, Ohtsu A, Tahara M.

Oncotarget. 2017 Jun 27;8(37):61786-61799. doi: 10.18632/oncotarget.18692. eCollection 2017 Sep 22.

40.

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.

Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Fujii S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K.

Br J Cancer. 2017 Nov 7;117(10):1450-1458. doi: 10.1038/bjc.2017.308. Epub 2017 Oct 3.

41.

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.

Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I.

Ann Oncol. 2017 Dec 1;28(12):2932-2942. doi: 10.1093/annonc/mdx514. Review.

42.

[Current Status and Future Perspectives of SCRUM-Japan].

Ohtsu A, Goto K, Yoshino T, Okamoto W, Tsuchihara K.

Gan To Kagaku Ryoho. 2017 Aug;44(8):621-626. Review. Japanese.

PMID:
28860428
43.

Age-associated mRNA expression changes in bovine endometrial cells in vitro.

Tanikawa N, Ohtsu A, Kawahara-Miki R, Kimura K, Matsuyama S, Iwata H, Kuwayama T, Shirasuna K.

Reprod Biol Endocrinol. 2017 Aug 14;15(1):63. doi: 10.1186/s12958-017-0284-z.

44.

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.

Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T, Mochizuki N, Nomura S, Doi T, Sato A, Ohtsu A, Yoshino T.

Lancet Oncol. 2017 Sep;18(9):1172-1181. doi: 10.1016/S1470-2045(17)30425-4. Epub 2017 Jul 28.

PMID:
28760399
45.

Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma.

Hatogai K, Fujii S, Kojima T, Daiko H, Nomura S, Doi T, Kitano S, Ohtsu A, Takiguchi Y, Yoshino T, Ochiai A.

J Cancer Res Clin Oncol. 2017 Nov;143(11):2351-2361. doi: 10.1007/s00432-017-2482-7. Epub 2017 Jul 29.

PMID:
28756492
46.

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer.

Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS.

Mol Cancer Ther. 2017 Oct;16(10):2215-2222. doi: 10.1158/1535-7163.MCT-16-0895. Epub 2017 Jul 17.

47.

Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.

Saito A, Isoda A, Kojima M, Yokohama A, Tsukune Y, Sasaki M, Ito S, Ohtsu A, Koike M, Murayama K, Moriya K, Tamura H, Matsumoto M, Nakahashi H, Tanosaki S, Sakura T, Kawamura T, Miyanaga T, Nakamura N, Murakami H, Handa H, Tsukamoto N.

Int J Hematol. 2017 Nov;106(5):681-690. doi: 10.1007/s12185-017-2297-y. Epub 2017 Jul 7.

PMID:
28687991
48.

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data.

Fuchs CS, Muro K, Tomasek J, Van Cutsem E, Cho JY, Oh SC, Safran H, Bodoky G, Chau I, Shimada Y, Al-Batran SE, Passalacqua R, Ohtsu A, Emig M, Ferry D, Chandrawansa K, Hsu Y, Sashegyi A, Liepa AM, Wilke H.

J Gastric Cancer. 2017 Jun;17(2):132-144. doi: 10.5230/jgc.2017.17.e16. Epub 2017 Jun 16.

49.

Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.

Kim TY, Yen CJ, Al-Batran SE, Ferry D, Gao L, Hsu Y, Cheng R, Orlando M, Ohtsu A.

Gastric Cancer. 2018 Mar;21(2):276-284. doi: 10.1007/s10120-017-0737-2. Epub 2017 Jun 20.

PMID:
28634748
50.

Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).

Shitara K, Doi T, Nagano O, Fukutani M, Hasegawa H, Nomura S, Sato A, Kuwata T, Asai K, Einaga Y, Tsuchihashi K, Suina K, Maeda Y, Saya H, Ohtsu A.

Gastric Cancer. 2017 Nov;20(6):1004-1009. doi: 10.1007/s10120-017-0720-y. Epub 2017 May 2.

PMID:
28466360

Supplemental Content

Support Center